当前位置:首页 - 行情中心 - 仟源医药(300254) - 财务分析 - 利润表

仟源医药

(300254)

  

流通市值:19.71亿  总市值:22.30亿
流通股本:2.27亿   总股本:2.57亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入351,884,456.08173,800,715.3870,786,344.11611,473,385.33
  营业收入351,884,456.08173,800,715.3870,786,344.11611,473,385.33
二、营业总成本340,846,294.47170,452,586.99784,341,269.05552,167,468.27
  营业成本118,224,376.4657,396,288.28284,037,044.8197,366,071.05
  税金及附加4,814,387.382,069,683.9711,875,494.557,952,681.02
  销售费用111,822,853.1859,557,515.75272,592,555.02194,954,237.54
  管理费用69,418,991.9433,411,863.32143,526,100.7897,207,255.2
  研发费用24,591,506.212,738,978.0550,797,571.3337,164,425.08
  财务费用11,974,179.315,278,257.6221,512,502.5717,522,798.38
  其中:利息费用12,003,737.985,337,217.3721,631,274.1217,626,899.56
  其中:利息收入118,894.0690,042.54245,508.66206,977.16
三、其他经营收益
  加:公允价值变动收益---18,934,476-
  加:投资收益-2,974,955.81859,682.153,971,475.891,469,358.04
  资产处置收益--8,941,963.337,943,493.79
  资产减值损失(新)-1,285,949.81-7,873.66-1,204,587.771,246,857.59
  信用减值损失(新)538,587.21338,096.79-6,831,283.97-2,545,129.87
  其他收益2,515,687.271,167,337.167,387,605.233,433,376.27
四、营业利润9,831,530.475,705,370.7579,775,771.7770,853,872.88
  加:营业外收入9,799,637.37,729,00018,917,67512,238,913.39
  减:营业外支出438,124.3645,541.247,899,611.615,723,452.46
五、利润总额19,193,043.4113,388,829.5190,793,835.1677,369,333.81
  减:所得税费用7,474,829.75,422,064.6134,356,521.5328,898,536.63
六、净利润11,718,213.717,966,764.956,437,313.6348,470,797.18
(一)按经营持续性分类
  持续经营净利润12,131,711.048,188,319.6759,605,414.7348,470,797.18
  终止经营净利润-413,497.33-221,554.77-3,168,101.1-
(二)按所有权归属分类
  归属于母公司股东的净利润4,285,822.493,342,275.1424,850,904.5322,327,426.51
  少数股东损益7,432,391.224,624,489.7631,586,409.126,143,370.67
  扣除非经常损益后的净利润5,325,564.391,706,208.2731,755,382.4817,526,985.32
七、每股收益
  (一)基本每股收益0.020.010.10.09
  (二)稀释每股收益0.020.010.10.09
九、综合收益总额11,718,213.717,966,764.956,437,313.6348,470,797.18
  归属于母公司股东的综合收益总额4,285,822.493,342,275.1424,850,904.5322,327,426.51
  归属于少数股东的综合收益总额7,432,391.224,624,489.7631,586,409.126,143,370.67
公告日期2026-08-252026-04-282026-04-282025-10-30
审计意见(境内)标准无保留意见
TOP↑